Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Feb;59(2):243–246. doi: 10.1038/bjc.1989.49

The effect of intensity of administered treatment on the outcome of germ cell tumours treated with POMB/ACE chemotherapy.

S M Crawford 1, E S Newlands 1, R H Begent 1, G J Rustin 1, K D Bagshawe 1
PMCID: PMC2246998  PMID: 2467683

Abstract

In order to assess the importance of the intensity of administration of chemotherapy in the management of advanced germ cell tumours we have calculated indices of chemotherapy. These have been used to compare the treatment given to patients who subsequently relapsed with matched controls who did not relapse. Two of these indices (alpha and beta) are derived from the doses of drugs whose dose is varied (cisplatinum, methotrexate and etoposide). These indices showed significant variation between cases and controls. Indices gamma and delta are derived from drugs whose dose is not varied. They showed no significant differences between the two groups. These results emphasise the importance of ensuring that patients with these curable cancers receive adequate doses of chemotherapy.

Full text

PDF
243

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carde P., MacKintosh F. R., Rosenberg S. A. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol. 1983 Feb;1(2):146–153. doi: 10.1200/JCO.1983.1.2.146. [DOI] [PubMed] [Google Scholar]
  2. Dembo A. J. Time-dose factors in chemotherapy: expanding the concept of dose-intensity. J Clin Oncol. 1987 May;5(5):694–696. doi: 10.1200/JCO.1987.5.5.694. [DOI] [PubMed] [Google Scholar]
  3. Einhorn L. H. Have new aggressive chemotherapy regimens improved results in advanced germ cell tumors? Eur J Cancer Clin Oncol. 1986 Nov;22(11):1289–1293. doi: 10.1016/0277-5379(86)90135-5. [DOI] [PubMed] [Google Scholar]
  4. Frei E., 3rd, Canellos G. P. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980 Oct;69(4):585–594. doi: 10.1016/0002-9343(80)90472-6. [DOI] [PubMed] [Google Scholar]
  5. Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984 Nov;2(11):1281–1288. doi: 10.1200/JCO.1984.2.11.1281. [DOI] [PubMed] [Google Scholar]
  6. Levin L., Hryniuk W. M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol. 1987 May;5(5):756–767. doi: 10.1200/JCO.1987.5.5.756. [DOI] [PubMed] [Google Scholar]
  7. Newlands E. S., Bagshawe K. D., Begent R. H., Rustin G. J., Crawford S. M., Holden L. Current optimum management of anaplastic germ cell tumours of the testis and other sites. Br J Urol. 1986 Jun;58(3):307–314. doi: 10.1111/j.1464-410x.1986.tb09061.x. [DOI] [PubMed] [Google Scholar]
  8. Newlands E. S., Begent R. H., Rustin G. J., Parker D., Bagshawe K. D. Further advances in the management of malignant teratomas of the testis and other sites. Lancet. 1983 Apr 30;1(8331):948–951. doi: 10.1016/s0140-6736(83)92079-2. [DOI] [PubMed] [Google Scholar]
  9. Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. Report from the Medical Research Council Working Party on Testicular Tumours. Lancet. 1985 Jan 5;1(8419):8–11. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES